Dossier assessment

Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Symptomatic treatment of adult women of reproductive age with endometriosis who have a history of previous medical or surgical treatment

Result of dossier assessment:

Women who are eligible for treatment with dienogest: added benefit not proven
Women who are not (or no longer) eligible for treatment with dienogest: added benefit not proven

Project no.: A23-117
Commission: Commission awarded on 29.11.2023 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Reproductive health and birth
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A23-117_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.